Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Breast Cancer Treatment: To tARget or Not? That is the Question

Alexandra Stone
,
Kevin Lin
,
Ghanshyam H. Ghelani
ORCID logo ,
Sanik Patel
,
Sam Benjamin
,
Stephen Graziano
,
Leszek Kotula
* ORCID logo
Version 1 : Received: 23 October 2023 / Approved: 23 October 2023 / Online: 24 October 2023 (05:51:15 CEST)

A peer-reviewed article of this Preprint also exists.

Stone, A.; Lin, K.M.; Ghelani, G.H.; Patel, S.; Benjamin, S.; Graziano, S.; Kotula, L. Breast Cancer Treatment: To tARget or Not? That Is the Question. Cancers 2023, 15, 5664. Stone, A.; Lin, K.M.; Ghelani, G.H.; Patel, S.; Benjamin, S.; Graziano, S.; Kotula, L. Breast Cancer Treatment: To tARget or Not? That Is the Question. Cancers 2023, 15, 5664.

Abstract

To assess AR’s role in TNBC treatment, various existing and completed clinical trials targeting AR or co-targeting AR with other pertinent signaling molecules were analyzed. Cyclin-dependent kinase 4/6 (CDK4/6), cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17 lyase), and the phosphatidylinositol 3kinase (PI3K)/protein kinase B (AKT) signaling pathway were some of the most prevalent biomarkers used in combination therapy with AR inhibitors in these trials. Studying how AR functions in tandem with these molecules can have increasing breakthroughs in the treatment options for TNBC. Previous studies have been largely unsuccessful in utilizing AR as the sole drug target for systemic targeted treatment in TNBC. However, there is a lack of other commonly used drug target biomarkers in the treatment of this disease, as well. Thus, analyzing the clinical benefit rate (CBR) within clinical trials that are using combination therapy can prove to be imperative to the progression of improving treatment options and prognoses.

Keywords

AR; TNBC; CDK4/6; CYP17 lyase; PI3K/AKT; ER; PR; HER2; DHT

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.